Systems Biology of Early Atopy
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: * To study the role and interrelationships of established and novel clinical, environmental, biological, and genetic prenatal and early-life factors in the development of allergic diseases through age 3 years, with an emphasis on atopic dermatitis and food allergy * To apply systems biology to identify mechanisms and biomarkers underlying the development of food allergy, atopic dermatitis, and their endotypes * To collect, process, and assay or store environmental and biological samples for current and future use in the study of allergic disease development
Conditions:
🦠 Allergic Diseases 🦠 Food Allergy 🦠 Atopic Dermatitis
🗓️ Study Start (Actual) 18 March 2021
🗓️ Primary Completion (Estimated) September 2028
✅ Study Completion (Estimated) September 2028
👥 Enrollment (Estimated) 2500
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 Little Rock, Arkansas, United States
📍 Stanford, California, United States
📍 Denver, Colorado, United States
📍 Baltimore, Maryland, United States
📍 Boston, Massachusetts, United States
📍 Detroit, Michigan, United States
📍 New York, New York, United States
📍 Chapel Hill, North Carolina, United States
📍 Cincinnati, Ohio, United States
📍 Nashville, Tennessee, United States
📍 Houston, Texas, United States
📍 Madison, Wisconsin, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • Pregnant Women-
    • Pregnant women who meet all of the following criteria are eligible for enrollment as study participants:
    • 1. Age 18 years or older
    • 2. Able to understand the oral and written instructions associated with study visits and procedures and provide informed consent
    • 3. Pregnant at any stage
    • 4. Planning to give birth at a study-site designated center
    • 5. Agrees to enroll offspring into the study at birth
    • 6. In the case of multiple gestation, agrees to enroll only one child who will be selected by randomized birth order
    • Biological Fathers-
    • Biological fathers who meet all of the following criteria are eligible for enrollment as study participants:
    • 1. Age 18 years or older
    • 2. Able to understand the oral and written instructions associated with study visits and procedures and provide informed consent

    Exclusion Criteria:

    • Pregnant Women-
    • Pregnant women who meet any of these criteria are not eligible for enrollment:
    • 1. Inability or unwillingness to comply with study protocol
    • 2. Serious pregnancy complication (in the judgement of the investigator) prior to enrollment
    • 3. Fetus has a major chromosomal anomaly
    • 4. Plans to move and would not be available for in-person visits at a study site
    • 5. Plans to give up her child for adoption at birth
    • 6. Pregnancy is the result of an egg donation
    • Infants-
    • Infants who meet any of these criteria are not eligible for enrollment:
    • 1. Delivered earlier than 34 weeks of gestation
    • 2. Sibling already enrolled
    • 3. Born with a significant birth defect or medical condition, and in the judgment of the investigators, participation is not in the infant's best interest
    • Biological Father-
    • 1. Biological fathers who are unable or unwilling to comply with the study protocol as it pertains to the biological father's participation are not eligible for enrollment
    • ----Note Regarding Legal Guardians who are not the Biological Parents:
    • 1. At screening for enrollment of either the mother or the child, if the biological mother intends to give the infant up for adoption, neither the mother nor the child are eligible for enrollment
    • 2. If the biological mother gives up legal guardianship of the child during the child's follow-up period, the child may remain enrolled as long as the new legal guardian:
    • * Agrees to meet the child's study requirements, and
    • * Provides written informed consent for the child's continued participation.
    • 3. Throughout the protocol where it refers to the mother, father, or parent answering questionnaires about the child or collecting samples from the child and the child's primary home, the legal guardian who provides consent for the child's participation may complete those procedures
Ages Eligible for Study: 0 Years to N/A (CHILD, ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 5 March 2021
  • First Submitted that Met QC Criteria 10 March 2021
  • First Posted 15 March 2021

Study Record Updates

  • Last Update Submitted that Met QC Criteria 23 April 2024
  • Last Update Posted 24 April 2024
  • Last Verified April 2024